|
1
|
Siegel RL, Miller KD, Fuchs HE and Jemal
A: Cancer Statistics, 2021. CA Cancer J Clin. 71:7–33. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rojas V, Hirshfield KM, Ganesan S and
Rodriguez-Rodriguez L: Molecular characterization of epithelial
ovarian cancer: Implications for diagnosis and treatment. Int J Mol
Sci. 17:21132016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Giampaolino P, Della Corte L, Foreste V,
Vitale SG, Chiofalo B, Cianci S, Zullo F and Bifulco G: Unraveling
a difficult diagnosis: The tricks for early recognition of ovarian
cancer. Minerva Med. 110:279–291. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Stewart C, Ralyea C and Lockwood S:
Ovarian cancer: An integrated review. Semin Oncol Nurs. 35:151–156.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rupaimoole R and Slack FJ: MicroRNA
therapeutics: Towards a new era for the management of cancer and
other diseases. Nat Rev Drug Discov. 16:203–222. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bader AG: miR-34-a microRNA replacement
therapy is headed to the clinic. Front Genet. 3:1202012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ottosen S, Parsley TB, Yang L, Zeh K, van
Doorn LJ, van der Veer E, Raney AK, Hodges MR and Patick AK: In
vitro antiviral activity and preclinical and clinical resistance
profile of miravirsen, a novel anti-hepatitis C virus therapeutic
targeting the human factor miR-122. Antimicrob Agents Chemother.
59:599–608. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chen SN, Chang R, Lin LT, Chern CU, Tsai
HW, Wen ZH, Li YH, Li CJ and Tsui KH: MicroRNA in Ovarian cancer:
Biology, pathogenesis, and therapeutic opportunities. Int J Environ
Res Public Health. 16:15102019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zheng H, Liu JY, Song FJ and Chen KX:
Advances in circulating microRNAs as diagnostic and prognostic
markers for ovarian cancer. Cancer Biol Med. 10:123–130.
2013.PubMed/NCBI
|
|
10
|
Resnick KE, Alder H, Hagan JP, Richardson
DL, Croce CM and Cohn DE: The detection of differentially expressed
microRNAs from the serum of ovarian cancer patients using a novel
real-time PCR platform. Gynecol Oncol. 112:55–59. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Llaurado M, Majem B, Altadill T, Lanau L,
Castellví J, Sánchez-Iglesias JL, Cabrera S, De la Torre J,
Díaz-Feijoo B, Pérez-Benavente A, et al: MicroRNAs as prognostic
markers in ovarian cancer. Mol Cell Endocrinol. 390:73–84. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu J, Yoo J, Ho JY, Jung Y, Lee S, Hur SY
and Choi YJ: Plasma-derived exosomal miR-4732-5p is a promising
noninvasive diagnostic biomarker for epithelial ovarian cancer. J
Ovarian Res. 14:592021. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li G, Ao S, Hou J and Lyu G: Low
expression of miR-125a-5p is associated with poor prognosis in
patients with gastric cancer. Oncol Lett. 18:1483–1490.
2019.PubMed/NCBI
|
|
14
|
Pfaffl MW: A new mathematical model for
relative quantification in real-time RT-PCR. Nucleic Acids Res.
29:e452001. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tang Z, Li C, Kang B, Gao G, Li C and
Zhang Z: GEPIA: A web server for cancer and normal gene expression
profiling and interactive analyses. Nucleic Acids Res. 45((W1)):
W98–W102. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bignone PA, Lee KY, Liu Y, Emilion G,
Finch J, Soosay AE, Charnock FM, Beck S, Dunham I, Mungall AJ and
Ganesan TS: RPS6KA2, a putative tumour suppressor gene at 6q27 in
sporadic epithelial ovarian cancer. Oncogene. 26:683–700. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fan L, Yang H, Zhang B and Ding H: MCUR1
is a prognostic biomarker for ovarian cancer patients. Cancer
Biomark. 33:311–316. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chang X and Dong Y: CACNA1C is a
prognostic predictor for patients with ovarian cancer. J Ovarian
Res. 14:882021. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang K, Guan C, Shang X, Ying X, Mei S,
Zhu H, Xia L and Chai Z: A bioinformatic analysis: The
overexpression and clinical significance of FCGBP in ovarian
cancer. Aging (Albany NY). 13:7416–7429. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chen L, Hou J, You B, Song F, Tu X and
Cheng X: An analysis regarding the prognostic significance of mavs
and its underlying biological mechanism in ovarian cancer. Front
Cell Dev Biol. 9:7280612021. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang M and Zhao L: CKAP2 promotes ovarian
cancer proliferation and tumorigenesis through the FAK-ERK pathway.
DNA Cell Biol. 36:983–990. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang RR, Wang LM and Shen JJ:
Overexpression of miR-32 inhibits the proliferation and metastasis
of ovarian cancer cells by targeting BTLA. Eur Rev Med Pharmacol
Sci. 24:4671–4678. 2020.PubMed/NCBI
|
|
23
|
Zhai DK, Liu B, Bai XF and Wen JA:
Identification of biomarkers and pathway-related modules involved
in ovarian cancer based on topological centralities. J BUON.
21:208–220. 2016.PubMed/NCBI
|
|
24
|
Wang YW, Zhao S, Yuan XY, Liu Y, Zhang K,
Wang J, Zhu J and Ma R: miR-4732-5p promotes breast cancer
progression by targeting TSPAN13. J Cell Mol Med. 23:2549–2557.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Omura T, Shimada Y, Nagata T, Okumura T,
Fukuoka J, Yamagishi F, Tajika S, Nakajima S, Kawabe A and Tsukada
K: Relapse-associated microRNA in gastric cancer patients after S-1
adjuvant chemotherapy. Oncol Rep. 31:613–618. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tang X, Liu S, Cui Y and Zhao Y:
MicroRNA-4732 is downregulated in non-small cell lung cancer and
inhibits tumor cell proliferation, migration, and invasion. Respir
Med Res. 80:1008652021.PubMed/NCBI
|
|
27
|
Hu Y, Bai J, Zhou D, Zhang L, Chen X, Chen
L, Liu Y, Zhang B, Li H and Yin C: The miR-4732-5p/XPR1 axis
suppresses the invasion, metastasis, and epithelial-mesenchymal
transition of lung adenocarcinoma via the PI3K/Akt/GSK3β/Snail
pathway. Mol Omics. 18:417–429. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kim J, Yu L, Chen W, Xu Y, Wu M, Todorova
D, Tang Q, Feng B, Jiang L, He J, et al: Wild-Type p53 promotes
cancer metabolic switch by inducing PUMA-Dependent suppression of
oxidative phosphorylation. Cancer Cell. 35:191–203. e82019.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Alevriadou BR, Patel A, Noble M, Ghosh S,
Gohil VM, Stathopulos PB and Madesh M: Molecular nature and
physiological role of the mitochondrial calcium uniporter channel.
Am J Physiol Cell Physiol. 320:C465–C482. 2021. View Article : Google Scholar : PubMed/NCBI
|
